Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations.
Julia K. Rotow(Dana-Farber Cancer Institute), Xiuning Le(The University of Texas MD Anderson Cancer Center), Sarah Gordon(Virginia Commonwealth University), Susan C. Scott(Johns Hopkins University), Melissa L. Johnson(Tennessee Oncology), Danny Nguyen(Harbin Medical University), A.I. Spira, Shetal Patel(University of North Carolina at Chapel Hill), Haobin Chen(Washington University in St. Louis), James Stevenson(Cleveland Clinic), Catherine A. Shu(Columbia University Irving Medical Center), Christina S. Baik(University of Washington), Aakash Desai(University of Alabama at Birmingham), Balazs Halmos(Montefiore Medical Center), Jamie Feng, Anastasios Dimou(Mayo Clinic), Jiaxin Niu(The University of Texas MD Anderson Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Kamya Sankar(Cedars-Sinai Medical Center), Amin Benyounes(Virginia Cancer Institute)
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
|Annals of Oncology|2020|443
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
|Annals of Oncology|2019|413